Previous Close | 2.4800 |
Open | 2.4600 |
Bid | 2.4200 x 0 |
Ask | 2.4400 x 0 |
Day's Range | 2.4200 - 2.4900 |
52 Week Range | 1.0600 - 3.1000 |
Volume | |
Avg. Volume | 78,730 |
Market Cap | 146.391M |
Beta (5Y Monthly) | 1.73 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4820 |
Earnings Date | Mar 01, 2023 - Mar 06, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.25 |
Here is how DICE Therapeutics, Inc. (DICE) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year.
Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging ...
Oncolytics Biotech® Inc.'s (NASDAQ: ONCY) (TSX: ONC) Chinese partner Adlai Nortye today announced interim results from a multicenter, single-arm bridging clinical trial to evaluate the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced/metastatic HR+/HER2- breast cancer. The data were featured in a poster presented yesterday at the San Antonio Breast Cancer Symposium (SABCS), which is being held at the Henry B. González C